Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Jade Biosciences, Inc. (JBIO)
Company Research
Source: GlobeNewswire
JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human clinical trial in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027Third development candidate, JADE301, nominated; Phase 1 clinical trial expected to commence in the first half of 2027$336 million of cash, cash equivalents, and investments as of December 31st, 2025 expected to provide runway into the first half of 2028 SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the fourth quarter and full
Show less
Read more
Impact Snapshot
Event Time:
JBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JBIO alerts
High impacting Jade Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
JBIO
News
- Jade Biosciences (JBIO) had its price target raised by HC Wainwright from $25.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Jade Biosciences (JBIO) had its price target raised by BTIG Research from $28.00 to $39.00. They now have a "buy" rating on the stock.MarketBeat
- Jade Biosciences (JBIO) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Jade Biosciences (JBIO) had its price target raised by Guggenheim from $17.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
- Jade Biosciences (JBIO) was upgraded by William Blair to "strong-buy".MarketBeat
JBIO
Earnings
- 11/13/25 - Beat
JBIO
Sec Filings
- 3/6/26 - Form S-8
- 3/6/26 - Form POS
- 3/6/26 - Form POS
- JBIO's page on the SEC website